Life Sciences

  • November 13, 2026

    Supplement Makers Say FDA Added Illegal Label Review

    A health advocacy group and three dietary supplement sellers urged a D.C. federal judge Friday to rule the U.S. Food and Drug Administration overstepped when it rejected over a hundred label claims for supplement products that connected certain nutrients to health outcomes.

  • November 13, 2026

    OpenAI Sued Over AI Attention Patent Infringement Claims

    A Texas technology company has sued OpenAI, claiming it is infringing a set of patents covering artificial intelligence attention, the same day it sued Anthropic on similar claims.

  • November 13, 2026

    FTC Challenges $3.5B Veterinary Supplies Merger

    The Federal Trade Commission sought Friday to block Covetrus Inc.'s planned $3.5 billion purchase of "its closest competitor" for veterinary products, MWI Veterinary Supply Inc., in a New York federal court complaint backed by more than a dozen state attorneys general.

  • November 12, 2026

    Anthropic, OpenAI Face Suit To Halt 'Insane' AI Development

    Nonprofits sued Anthropic, Google, Meta Platforms, OpenAI and SpaceXSI in California state court Thursday seeking to freeze the "insane" and "dangerous" development of advanced artificial intelligence that can escape human control, arguing the companies have no realistic way to stop the "catastrophic" events their own executives predict could occur.

  • November 12, 2026

    Masimo, ITC Tell Justices To Skip Apple Watch Ban Appeal

    Masimo Corp. and the U.S. International Trade Commission said Thursday that the U.S. Supreme Court should ignore Apple's arguments that the Federal Circuit degraded the agency's domestic industry requirement by sustaining a finding that Apple watches infringed a pair of patents.

  • November 12, 2026

    Squires Grants Another 5 PTAB Petitions, Denies 2

    U.S. Patent and Trademark Office Director John Squires has instituted five new patent challenges, largely in the pharmaceutical industry, in one of his final mass orders.

  • November 12, 2026

    TikTok Backs School District In MDL Trial Witness Fight

    School district plaintiffs on Wednesday opposed a bid by YouTube, Snap and Meta to exclude late-disclosed witnesses from an upcoming bellwether trial in social media addiction multidistrict litigation, noting that defendant TikTok agreed the school district witnesses can be added if TikTok USDS Joint Venture's new CEO can testify as well.

  • November 12, 2026

    Anthropic Accused Of Infringing AI Attention Patents

    A Texas technology company sued Anthropic on Thursday claiming it was infringing a set of patents covering AI attention for training when working on its marquee chatbot model Claude.

  • November 12, 2026

    Ex-Cravath Staffer Charged With Insider Trading

    A former employee at Cravath Swaine & Moore LLP on Thursday was arrested and charged with insider trading for allegedly exploiting nonpublic information about major deals involving the firm's clients, including Paramount Skydance Corp.'s $110 billion acquisition of Warner Bros. Discovery Inc.

  • November 10, 2026

    Costco Can't End Dog Food Heart Risk Suit Yet, Buyers Say

    Dog owners on Monday told a Washington federal judge that Costco's bid to dismiss their proposed class action alleging that its grain-free dog food contributes to canine heart disease ignores their factual allegations, saying that the company is cherry-picking from studies about the risk.

  • November 10, 2026

    Pharma Co. Investors Ink $4M Deal In FDA Hurdle Suit

    Verrica Pharmaceuticals and a group of investors have reached a $4 million deal to end claims that the company hid obstacles it faced in obtaining U.S. Food and Drug Administration approval for its lead product.

  • November 10, 2026

    LA Cannabis Retailer Sued Over Email 'Spy Pixels'

    A Los Angeles dispensary placed "malicious" code in marketing emails that spied on a consumer and recorded when she opened the messages and her location, forwarding the information to data-broker vendors, according to a California state lawsuit which seeks $1,000 per email and $5,000 per privacy violation.

  • November 10, 2026

    Idaho Judge Stays Abortion Relief, Citing 9th Circ. Ruling

    An Idaho federal judge on Tuesday stayed his finding that the state would violate the 14th Amendment by criminalizing certain abortions performed by a doctor challenging the state's abortion laws, saying he is bound by a Ninth Circuit decision he "strongly disagrees" with.

  • November 10, 2026

    Drugmaker Inks $2.5M Deal In Failed Weight Loss Drug Suit

    Drugmaker Skye Bioscience Inc. has reached a $2.5 million settlement with investors that would end a proposed securities class action alleging the company overhyped a weight-loss drug, causing its stock price to plummet once the truth came to light.

  • November 10, 2026

    11th Circ. Asked To Nix Penalties For Captive Deductions

    The U.S. Tax Court improperly imposed additional accuracy-related penalties against a Florida business for deductions it took for microcaptive insurance expenses, the business's owner told the Eleventh Circuit, saying the Tax Court's analysis of the case can't be reconciled with binding circuit precedent.

  • November 10, 2026

    Stryker Shorted Wash. Workers On Breaks, Wages, Suit Says

    A medical device company failed to provide Washington hourly workers with required meal and rest breaks, underpaid their wages and restricted their ability to discuss their pay, according to a proposed class action removed to Washington federal court.

  • November 10, 2026

    Oura Buys Healthcare AI Platform In $625M Deal

    Health intelligence platform Oura, advised by Latham & Watkins LLP, on Tuesday unveiled plans to acquire artificial intelligence-native primary care company Counsel Health, led by DLA Piper, in a $625 million deal.

  • November 10, 2026

    Judge Again Declines Recusal Over Wife's Blank Rome Ties

    The Pennsylvania state judge overseeing Philadelphia's Zantac mass tort litigation has again rejected claims that he might have a conflict of interest because his wife's firm represents a defendant in one of more than 500 such cases, pointing out that the case in question has been resolved.

  • November 10, 2026

    Pharma Co. Invatech Can Stay In Chapter 11, For Now

    A New Jersey bankruptcy judge on Tuesday denied the Office of the U.S. Trustee's bid to convert Invatech's bankruptcy to a Chapter 7 as the former generic pharmaceutical group works to wrap up an administratively insolvent Chapter 11.

  • November 10, 2026

    Judge Will Reduce 'Shocking' $88M Mesh Bellwether Verdict

    A Massachusetts federal judge said Tuesday she will reduce an $88 million verdict awarded to an Alabama couple in the first bellwether hernia mesh trial against Medtronic subsidiary Covidien LP, saying the award appeared to be "the product of passion."

  • November 09, 2026

    Fed. Circ. Presses Medytox On Bid To Save ITC Theft Case

    A Federal Circuit judge on Monday appeared perplexed by medical aesthetics provider Medytox Inc.'s position that the U.S. International Trade Commission wrongly rejected its claim that a rival stole its anti-wrinkle technology, saying Medytox's argument "has nothing to do" with the ruling.

  • November 09, 2026

    9th Circ. Undoes Royalties Award In Anesthetic Contract Case

    The Ninth Circuit has set aside a judgment directing Research Development Foundation to pay royalties to Pacira Pharmaceuticals Inc. in a contract dispute involving the anesthetic Exparel, further remanding the case for a recalculation of prejudgment interest.

  • November 09, 2026

    Ohio AG Asks To Streamline Drug Pricing Suit

    The attorney general of Ohio is seeking to amend its complaint accusing Express Scripts and several related entities of conspiring to raise prescription drug prices.

  • November 09, 2026

    FDA Orders New GLP-1 Risk Warnings Over Vision Loss

    The U.S. Food and Drug Administration on Monday said it is requiring new warnings on GLP-1 medications, the group of blockbuster drugs prescribed for diabetes and weight loss, for a serious, rare condition that can cause sudden and possibly permanent vision loss in one eye.

  • November 09, 2026

    Compass Submits Psilocybin Depression Drug To FDA

    Pharmaceutical company Compass Pathways announced Monday that it had submitted to the U.S. Food and Drug Administration a new drug application to treat treatment-resistant depression with psilocybin, the primary compound in psychoactive mushrooms.

Expert Analysis

  • Opinion

    NY Must Limit Interlocutory Appeals

    Author Photo

    The New York Legislature should act to reduce the Appellate Division's outsize caseload of interlocutory civil appeals in order to develop a faster, less expensive, fairer and more coherent civil justice system, says Judge Gerald Lebovits.

  • Planning Personal Phone Collections Before Discovery Begins

    Author Photo

    For counsel planning a personal phone collection as part of the litigation discovery process, it's important to take early steps to ensure that necessary information will be obtained without exposing unrelated information or running into access issues, says Jeremy Horowitz at MARA Forensics.

  • Calif. Sex Harassment Cases Clarify Limits On EFAA Waivers

    Author Photo

    Two recent rulings in California confirm that the plaintiff's knowledge drives waiver analysis under the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act, underscoring that employers should build a strong evidentiary record and pick their battles, says Ellen Connelly Cohen at Call & Jensen.

  • 2 Del. Rulings Show Postclosing Earnout Arrangement Risks

    Author Photo

    Two recent Delaware Court of Chancery decisions illustrate the contractual and fiduciary duty risks associated with earnout provisions in M&A transactions, offering lessons on allocating postclosing control, drafting enforceable earnout covenants and managing executives whose pay depends on the outcome, says Chris Brown at Taft.

  • Opinion

    Judges Must Turn To Merits Earlier To Fix Civil Justice System

    Author Photo

    The U.S. justice system is long overdue for a cultural shift that encourages judges to engage with the merits of a case from the outset, which would help to cut through procedural complexities and deliver high-quality justice efficiently and at lower cost, says Steven Kayman at Rottenberg Lipman.

  • How Analytical Advances Reshape Biologic Patent Strategy

    Author Photo

    As regulators shift away from relying on comparative clinical efficacy studies in biosimilar development, and more toward analytical data, practitioners should pay closer attention to post-translational modifications when evaluating patentability, says Gina Nellesen at Global Patent Group.

  • Series

    Open-Water Swimming Makes Me A Better Lawyer

    Author Photo

    Swimming long distances in open waters is not necessarily an escape from my intellectual property practice, but a complementary discipline that similarly rewards sustained attention, intellectual curiosity, resilience and the ability to pursue a distant objective without losing command of the immediate task, says Christina MacDougall at Morgan Lewis.

  • Opinion

    The Invisible AI Danger That May Undermine Legal Profession

    Author Photo

    A public database tracking cases involving hallucinations generated by artificial intelligence recently surpassed 2,200 entries, but the bigger risk underlying attorneys’ use of such tools is that they will slowly surrender their judgment to AI and lose analytical skills, says Massachusetts District Court Associate Justice Brian Palmucci.

  • How Cos. Using AI Agents Can Avoid Protected Data Incidents

    Author Photo

    For businesses whose deployed artificial intelligence agents could enter other companies' systems and steal protected data, deployers can take several steps before an incident to test the configured agent, such as limiting it to approved systems and destinations and requiring human escalation when tasks stall, says Steven Carlson at von Briesen & Roper.

  • FDA Classification Setback Bodes Well For Wound Care Cos.

    Author Photo

    A Georgia federal court's recent decision in MiMedx v. U.S. Food and Drug Administration constrains the FDA's analytical framework for classifying certain wound care products as biological products, carrying important ramifications for manufacturers seeking to avoid heightened regulatory requirements, say attorneys at Hyman Phelps.

  • Lessons For Cannabis Dispensaries From Web Tracking Suits

    Author Photo

    The trajectory of health-tracking litigation in Florida and elsewhere suggests that patient privacy claims will not disappear quickly, so dispensaries should audit their sites, tighten consent and align their disclosures with their actual practices, say attorneys at Buchanan Ingersoll.

  • How AI Could Help Judges Spot Their Own Biases

    Author Photo

    In close cases where there’s room for discretion, artificial intelligence could challenge judges’ implicit biases by running counterfactual tests at scale — but any judicial use of such tools would need guardrails, say Arnold Peter at Peter Law and Nancy Rapoport at University of Nevada.

  • 3 Eligibility Rulings Show Risks Of Broad Claim Constructions

    Author Photo

    Several recent decisions from the Federal Circuit, including its ruling in Berkeley v. W.W. Grainger, highlight the importance of identifying the inventive aspects of a patent early in the case so that patentees do not inadvertently read the inventive features out of their own claims, say attorneys at MoFo.

  • 3 Strategies To Reduce AI Sycophancy In Legal Work

    Author Photo

    The tendency of generative artificial intelligence models to tell users what they want to hear can reinforce attorneys’ confirmation bias when testing the strength of arguments, and it can’t simply be prompted away — but a few practices can help mitigate it, says Michael Ott at Ice Miller.

  • DOJ Directive Gives Contractors A Fraud Risk Road Map

    Author Photo

    For government contractors, the 10 factors described in the U.S. Department of Justice's recent corporate fraud enforcement directive function as a de facto scoring rubric for internal audits that mirrors what prosecutors will prioritize, say attorneys at Spencer Fane.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here